Advertisement

HLA-A*02-B*46 haplotype: an adverse prognostic factor in Han patients with nasopharyngeal carcinoma

  • Ruo-zheng Wang (王若峥)
  • Dian-gang Zhang (张典刚)
  • Ran Wu (吴 冉)
  • Yun-hui Hu (胡云辉)
  • Yan-chun Peng (彭艳春)
  • Cheng Chang (常 诚)
  • Tao Dong (董 涛)Email author
  • Xi-yan Wang (王喜艳)
Article

Abstract

Epidemiological studies have shown that human leukocyte antigen (HLA) allelic polymorphisms are closely correlated to susceptibility to nasopharyngeal carcinoma (NPC), and in a previous study, we showed that HLA-B*46 and HLA-A*02-B*46 haplotypes were strongly associated with NPC susceptibility. In this retrospective study, we investigated the phenotype of the HLA-A and HLA-B alleles and haplotypes and correlated these data to the clinical and pathological parameters of NPC to understand the role of HLA alleles and haplotypes in NPC prognosis. The cohort comprised 117 NPC patients from a Han population in Xinjiang. The local recurrence-free survival (LRFS), distant metastasis- free survival (DMFS), disease-free survival (DFS), and overall survival (OS) were analyzed. The 5-year DMFS of the HLA-A*02-B*46 haplotype carriers and non-carriers was 66.4% and 90.3%, respectively. In addition, age was found to be a prognostic factor for LRFS, DFS, and OS (P=0.032, 0.040, and 0.013, respectively). We found that the HLA-A*02-B*46 haplotype might be a prognostic marker in addition to the traditional TNM staging in patients with NPC.

Keywords

human leukocyte antigens phenotype nasopharyngeal carcinoma prognosis metastasis 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Tang MZ, Cai YL, Zheng YM, et al. Association between human leukocyte antigen and nasopharyngeal carcinoma. Yi Chuan (Chinese), 2012,34(12):1505–1512CrossRefGoogle Scholar
  2. 2.
    Horton R, Wilming L, Rand V, et al. Gene map of the extended human MHC. Nat Rev Genet, 2004,5(12):889–899CrossRefPubMedGoogle Scholar
  3. 3.
    Chin YM, Mushiroda T, Takahashi A, et al. HLA-A SNPs and amino acid variants are associated with nasopharyngeal carcinoma in Malaysian Chinese. Int J Cancer, 2015,136(3):678–687PubMedGoogle Scholar
  4. 4.
    Yu KJ, Gao X, Chen CJ, et al. Association of human leukocyte antigens with nasopharyngeal carcinoma in high-risk multiplex families in Taiwan. Hum Immunol, 2009,70(11):910–914CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Tang M, Zeng Y, Poisson A, et al. Haplotype-dependent HLA susceptibility to nasopharyngeal carcinoma in a Southern Chinese population. Genes Immun, 2010,11(4):334–342CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Wang R, Hu Y, Yindom LM, et al. Association analysis between HLA-A, -B, -C, -DRB1, and-DQB1 with nasopharyngeal carcinoma among a Han population in Northwestern China. Hum Immunol, 2014,75(3):197–202CrossRefPubMedGoogle Scholar
  7. 7.
    Lin Z, Guo Z, Xu Y, et al. Identification of a secondary promoter of CASP8 and its related transcription factor PURa. Int J Oncol, 2014,45(1):57–66PubMedPubMedCentralGoogle Scholar
  8. 8.
    Luo RZ, Zhong BL, Zong YS, et al. Histopathological characteristics of nasopharyngeal carcinoma in high incidence areas. Chin J Cancer (Chinese), 2001,20(8):473–475Google Scholar
  9. 9.
    Tang M, Lautenberger JA, Gao X, et al. The principal genetic determinants for nasopharyngeal carcinoma in China involve the HLA class I antigen recognition groove. PLoS Genet, 2012,8(11):e1003103CrossRefGoogle Scholar
  10. 10.
    Yuan J, Liu S, Yu Q, et al. Down-regulation of human leukocyte antigen class I (HLA-I) is associated with poor prognosis in patients with clear cell renal cell carcinoma. Acta Histochem, 2013,115(5):470–474CrossRefPubMedGoogle Scholar
  11. 11.
    Minami T, Minami T, Shimizu N, et al. Identification of erythropoietin receptor-derived peptides having the potential to induce cancer-reactive cytotoxic T lymphocytes from HLA-A24(+) patients with renal cell carcinoma. Int Immunopharmacol, 2014,20(1):59–65CrossRefPubMedGoogle Scholar
  12. 12.
    Tertipis N, Villabona L, Nordfors C, et al. HLA-A*02 in relation to outcome in human papillomavirus positive tonsillar and base of tongue cancer. Anticancer Res, 2014,34(5):2369–2375PubMedGoogle Scholar
  13. 13.
    Simons MJ, Chan SH, Wee GB, et al. Nasopharyngeal carcinoma and histocompatibility antigens. IARC Sci Publ, 1978,20:271–382PubMedGoogle Scholar
  14. 14.
    Hildesheim A, Apple RJ, Chen CJ, et al. Association of HLA class I and II alleles and extended haplotypes with nasopharyngeal carcinoma in Taiwan. J Natl Cancer Inst, 2002,94(23):1780–1789CrossRefPubMedGoogle Scholar
  15. 15.
    Hu SP, Day NE, Li DR, et al. Further evidence for an HLA related recessive mutation in nasopharyngeal carcinoma among the Chinese. Br J Cancer, 2005,92(5):967–970CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Lu CC, Chen JC, Jin YT, et al. Genetic susceptibility to nasopharyngeal carcinoma within the HLA-A locus in Taiwanese. Int J Cancer, 2003,103(6):745–751CrossRefPubMedGoogle Scholar
  17. 17.
    Sengupta S, den Boon JA, Chen IH, et al. Genome-wide expression profiling reveals EBV-associated inhibition of MHC class I expression in nasopharyngeal carcinoma. Cancer Res, 2006,66(16):7999–8006CrossRefPubMedGoogle Scholar
  18. 18.
    Han L, Lin SJ, Pan JJ, et al. Prognostic factors of 305 nasopharyngeal carcinoma patients treated with intensity-modulated radiotherapy. Chin J Cancer (Chinese), 2010,29(2):145–150CrossRefGoogle Scholar

Copyright information

© Huazhong University of Science and Technology and Springer-Verlag Berlin Heidelberg 2016

Authors and Affiliations

  • Ruo-zheng Wang (王若峥)
    • 1
  • Dian-gang Zhang (张典刚)
    • 1
  • Ran Wu (吴 冉)
    • 1
    • 2
  • Yun-hui Hu (胡云辉)
    • 1
  • Yan-chun Peng (彭艳春)
    • 3
  • Cheng Chang (常 诚)
    • 1
  • Tao Dong (董 涛)
    • 1
    • 3
    • 4
    Email author
  • Xi-yan Wang (王喜艳)
    • 1
  1. 1.Department of Head and Neck Radiation Oncologythe Affiliated Tumor Hospital of Xinjiang Medical UniversityUrumqiChina
  2. 2.Department of OncologyBazhou People’s Hospital of Mongolian Autonomous PrefectureKuerleChina
  3. 3.MRC Human Immunology UnitRadcliffe Department of Medicine, Oxford UniversityOxfordUK
  4. 4.Nuffield Department of MedicineOxford UniversityOxfordUK

Personalised recommendations